Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04595162 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

StatusNot Yet Recruiting
PhasePhase 1
Started2021-03-15
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 20, 2020 (before its estimated December 15, 2023 completion). Its status may not reflect the trial's current state.
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC019F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 6-12 subjects to receive GC019F therapy.
Trial Details
NCT Number NCT04595162
Lead Sponsor Peking University Third Hospital
Collaborators: Gracell Biotechnology Ltd.
Conditions B-cell Acute Lymphoblastic Leukemia
Enrollment 12 participants
Start Date 2021-03-15
Primary Completion 2023-12-15 (estimated)
Study Completion 2035-12-15 (estimated)
Updated on ClinicalTrials.gov 2020-10-20